PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
Actinium Pharmaceuticals, Inc. (ATNM)
1.780.01 (-0.56%)
1.75 - 1.81
1.03 - 2.41
122.5K / 296.7K (Avg.)
-1.36 | -1.31
Shows the trajectory of a company's cash-generation capacity. Consistent growth in operating and free cash flow suggests a robust, self-funding business model—crucial for value investors seeking undervalued, cash-rich opportunities.
-22.30%
Both yoy net incomes decline, with GNPX at -4.11%. Martin Whitman would view it as a broader sector or cyclical slump hitting profits.
24.17%
Some D&A expansion while GNPX is negative at -7.97%. John Neff would see competitor’s short-term profit advantage unless expansions here deliver big returns.
100.00%
Some yoy growth while GNPX is negative at -100.00%. John Neff would see competitor possibly managing deferrals more aggressively for short-term advantage.
-9.33%
Both cut yoy SBC, with GNPX at -0.02%. Martin Whitman would view it as an industry shift to reduce stock-based pay or a sign of reduced expansions.
-80.33%
Negative yoy working capital usage while GNPX is 15.37%. Joel Greenblatt would see more free cash if revenue remains unaffected, giving a short-term advantage.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
-46.04%
Negative yoy AP while GNPX is 0.00%. Joel Greenblatt would see quicker payments or less reliance on trade credit than competitor, unless expansions are hindered.
-249.09%
Both reduce yoy usage, with GNPX at -205.54%. Martin Whitman would suspect an industry or cyclical factor pulling back on these items.
-101.42%
Negative yoy while GNPX is 123.94%. Joel Greenblatt would see a near-term net income or CFO stability advantage unless competitor invests or writes down more aggressively.
-72.30%
Negative yoy CFO while GNPX is 3.71%. Joel Greenblatt would see a disadvantage in operational cash generation vs. competitor.
-455.28%
Both yoy lines negative, with GNPX at -867.78%. Martin Whitman would suspect a cyclical or broad capital spending slowdown in the niche.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
100.00%
We have some outflow growth while GNPX is negative at -655.51%. John Neff sees competitor possibly pulling back more aggressively from minor expansions or intangible invests.
-427.62%
Both yoy lines negative, with GNPX at -867.78%. Martin Whitman suspects a broader cyclical shift away from heavy investing across the niche.
No Data
No Data available this quarter, please select a different quarter.
53916.27%
We slightly raise equity while GNPX is negative at -100.00%. John Neff sees competitor possibly preserving share count or buying back shares.
No Data
No Data available this quarter, please select a different quarter.